Yonjin Ventures

Yonjin Venture LLC is a life sciences-focused venture capital firm established in 2018 and headquartered in Cambridge, Massachusetts. The firm operates as the North America and Europe investment arm of Shanghai-based Yongjin Group, founded in 1995, which positions itself as a diversified capital-markets financial-services institution. Yonjin's sister vehicle is China-based Yonghua Capital, and the two share parent-level resources and deal flow. Yonjin Venture's mandate is early- to mid-stage life sciences, specifically therapeutic drug discovery, diagnostics and medical devices, and it routinely participates as a syndicate co-investor alongside leading US biotech specialists rather than as a lead investor. The team is reported at roughly 10 people including 7 partners. Public portfolio companies include Rapafusyn Pharmaceuticals in drug discovery, its most recent investment in September 2025, CSA Medical, a Series D-II in September 2024, HistoSonics, a focused-ultrasound therapeutic platform, TECLens in ophthalmology devices, Libra Therapeutics in neurodegeneration, a Series A co-led with Boehringer Ingelheim Venture Fund, and OncoResponse in cancer-immunotherapy antibodies, co-invested alongside MD Anderson, ARCH Venture Partners, Canaan Partners, Redmile and GreatPoint. To date the firm has roughly 17 reported investments and one IPO exit, C4 Therapeutics, which went public in October 2020. Fund size and AUM are not publicly disclosed. As the North America and Europe arm of a Chinese financial-services group, Yonjin Ventures co-invests alongside leading US biotech specialists in early- to mid-stage therapeutics, diagnostics and medical devices.